Abstract | BACKGROUND: METHODS: A total of 419 LANPC patients who attained suboptimal response (stable disease or disease progression) according to the Response Evaluation in Solid Tumors (RECIST) guideline after initial IC were retrospectively included. They were divided into those who received additional cycles of re-induction regimen prior to RT (re-induction group, n = 87) and those who had no additional chemotherapy (direct to RT group, n = 332). Propensity score matching (PSM) was used to adjust for potential confounders. Tumor response and long-term survival were compared between two groups. RESULTS: After receiving a second IC regimen, 39.1% of the patients in re-induction group attained partial response; however, the tumor control of subsequent RT was not significantly improved when compared with direct to RT group (patients attaining complete response after RT 55.2% vs. 52.5%, P = 0.757). Patients who received re-induction therapy showed worse locoregional relapse-free survival (LRFS) and progression-free survival (PFS) than those proceeded directly to RT (3-year LRFS 75.7% vs. 83.1%, P = 0.005; 3-year PFS 62.4% vs. 68.3%, P = 0.037). The increased hematological toxicities were observed in re-induction group that included grade 3-4 anemia, thrombocytopenia and liver enzyme increase. CONCLUSION: Re-induction therapy decreased LRFS and PFS and increased toxicities among patients who attain suboptimal response to initial IC regimen, as compared with direct to RT strategy.
|
Authors | Ting Liu, Li-Ting Liu, Jie-Yi Lin, Bo-Wen Shen, Shan-Shan Guo, Sai-Lan Liu, Xue-Song Sun, Yu-Jing Liang, Mei-Juan Luo, Xiao-Yun Li, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 163
Pg. 185-191
(10 2021)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 34453953
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Elsevier B.V. All rights reserved. |
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
- Chemoradiotherapy
- Cisplatin
(therapeutic use)
- Humans
- Induction Chemotherapy
- Nasopharyngeal Carcinoma
(drug therapy, radiotherapy)
- Nasopharyngeal Neoplasms
(drug therapy, radiotherapy)
- Neoplasm Recurrence, Local
- Retrospective Studies
|